AbelZeta Competitors and Similar CompaniesClear all

AbelZeta's competitors and similar companies include Turning Point Therapeutics, Recordati, Agios Pharmaceuticals and Pharmstandard.

	AbelZeta AbelZeta (formerly known as Cellular Biomedicine Group) is a biopharmaceutical company that develops therapeutic solutions.	Turning Point Therapeutics Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases.	Recordati Recordati Industria Chimica e Farmaceutica is a company that manufactures and commercializes pharmaceutical products.	Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism.	Pharmstandard Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products.
Founding Date	Founding Date 2009	Founding Date 2013	Founding Date 1926	Founding Date 2008	Founding Date 2003
Type	Type Private	Type Subsidiary	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development pharma therapy	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development pharma
Locations	Locations Rockville, US HQ Shanghai, CN	Locations San Diego, US HQ	Locations Milan, IT HQ Campoverde, IT	Locations Cambridge, US HQ	Locations Dolgoprudny, RU HQ Kursk, RU Moscow, RU Petrovo Dalnee, RU Tomsk, RU Ufa, RU Vol'ginskii, RU
Employees	Employees 1261% decrease	Employees 474% decrease	Employees 4,580	Employees 53611% increase	Employees 1,77814% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 12 b	Valuation ($) 2.7 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $30.8m (FY, 2021)	Revenue (est.) €2.6b (FY, 2025)	Revenue (est.) $54m (FY, 2025)	Revenue (est.) ₽152.1b (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods €607.7m (FY, 2025)	Cost of goods $6.3m (FY, 2025)	Cost of goods ₽117b (FY, 2024)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit €2b (FY, 2025)	Gross profit $47.7m (FY, 2025)	Gross profit ₽35.2b (FY, 2024)
Net income	Net income N/A	Net income ($236.6m) (FY, 2021)	Net income €443.6m (FY, 2025)	Net income ($412.8m) (FY, 2025)	Net income ₽22.7b (FY, 2024)